- Drug Pipelines
- February 2024
- 80 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- November 2023
- 185 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- August 2022
- 117 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Report
- August 2022
- 119 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Report
- April 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Relenza is an antiviral drug used to treat influenza, commonly known as the flu. It is a neuraminidase inhibitor, meaning it works by blocking the activity of the neuraminidase enzyme, which is essential for the virus to spread within the body. Relenza is used to treat both seasonal and pandemic influenza, and is approved for use in adults and children over the age of five. It is usually taken as an inhaled powder, but can also be taken as an oral tablet.
Relenza is one of several drugs used to treat infectious diseases, which are caused by microorganisms such as bacteria, viruses, fungi, and parasites. Other drugs used to treat infectious diseases include antibiotics, antifungals, antivirals, and antiparasitics.
The Relenza market is highly competitive, with several companies offering the drug. These include GlaxoSmithKline, Novartis, Sanofi, and Mylan. Show Less Read more